Botulinum neurotoxin serotype A: A clinical update on non-cosmetic uses

American Journal of Health-System Pharmacy

Volumn 61, Issue SUPPL. 6, 2004, Pages

  Charles, P David ^a  

^a VANDERBILT UNIVERSITY   (United States)

Author keywords

Botulinum toxin A; Dosage; Drugs; Food and Drug Administration (U.S.); Skeletal muscle relaxants; Toxicity

Indexed keywords

ACETYLSALICYLIC ACID; ALCOHOL; AMANTADINE; BACLOFEN; BARBITURIC ACID DERIVATIVE; BENZATROPINE; BENZODIAZEPINE DERIVATIVE; BOTULINUM TOXIN A; BOTULINUM TOXIN B; BROMOCRIPTINE; BUTALBITAL; CARBAMAZEPINE; CARBIDOPA PLUS LEVODOPA; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLONAZEPAM; COSMETIC; DIAZEPAM; DOPAMINE RECEPTOR STIMULATING AGENT; ERGOT ALKALOID; GABAPENTIN; IBUPROFEN; KETOROLAC; LEVODOPA; MUSCLE RELAXANT AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PHENOL; PHENYTOIN; TRIHEXYPHENIDYL; UNINDEXED DRUG;

ANUS FISSURE; BLEPHAROSPASM; BONE PAIN; CEREBRAL PALSY; CLINICAL TRIAL; CONFERENCE PAPER; DETRUSOR DYSSYNERGIA; DIPLOPIA; DRUG APPROVAL; DRUG FORMULATION; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; DYSPHAGIA; DYSTONIA; ESOPHAGUS ACHALASIA; EYELID DISEASE; FOOD AND DRUG ADMINISTRATION; HEADACHE; HEMIFACIAL SPASM; HUMAN; HYPERHIDROSIS; HYPERSALIVATION; HYPERSENSITIVITY REACTION; INJECTION PAIN; INJURY; META ANALYSIS; MULTIPLE SCLEROSIS; MUSCLE WEAKNESS; MYALGIA; PAIN; PALLIATIVE THERAPY; PARALYSIS; PRIORITY JOURNAL; PTOSIS; SIDE EFFECT; SPASMODIC TORTICOLLIS; SPASTICITY; STRABISMUS; STROKE; SYSTEMATIC REVIEW; XEROSTOMIA; CONTROLLED CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; MULTICENTER STUDY; NEUROMUSCULAR DISEASE; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; REVIEW;

BOTULINUM TOXIN TYPE A; DOUBLE-BLIND METHOD; HEMIFACIAL SPASM; HUMANS; HYPERHIDROSIS; MULTICENTER STUDIES; NEUROMUSCULAR DISEASES; PAIN; RANDOMIZED CONTROLLED TRIALS;

EID: 16644391508     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/61.suppl_6.s11     Document Type: Conference Paper

References (85)

1. Botox package insert. Irvine, CA: Allergan Inc.; 2004 Jul.
2. Myobloc package insert. South San Francisco, CA: Elan Pharmaceuticals, Inc.; 2000 Dec.
3. Jankovic J, Brin MF. Botulinum toxin: historical perspective and potential new indications. Muscle Nerve Suppl. 1997; 6:S129-45.
4. Tejedor J, Rodriguez JM. Long-term outcome and predictor variables in the treatment of acquired esotropia with botulinum toxin. Invest Ophthalmol Vis Sci. 2001; 42:2542-6.
5. Tejedor J, Rodriguez JM. Early retreatment of infantile esotropia: comparison of reoperation and botulinum toxin. Br J Ophthalmol 1999; 83:783-7.
6. Chang LB, Tsai CP, Liao KK et al. Use of botulinum toxin A in the treatment of hemifacial spasm and blepharospasm. Zhonghua Yi Xue Za Zhi (Taipei). 1999; 62:1-5.
7. Arthurs B, Flanders M, Codere F et al. Treatment of blepharospasm with medication, surgery and type A botulinum toxin. Can J Ophthalmol. 1987; 22:24-8.
8. Sedano MJ, Trejo JM, Macarron JL et al. Continuous facial myokymia in multiple sclerosis: treatment with botulinum toxin. Eur Neurol. 2000; 43:137-40.
9. Polo KB, Jabbari B. Effectiveness of botulinum toxin type A against painful limb myoclonus of spinal cord origin. Mov Disord. 1994; 9:233-5.
10. Lu CS, Chen RS, Tsai CH. Double-blind, placebo-controlled study of botulinum toxin injections in the treatment of cervical dystonia. J Formos Med Assoc. 1995; 94:189-92.
11. Brans JW, Lindeboom R, Aramideh M et al. Long-term effect of botulinum toxin on impairment and functional health in cervical dystonia. Neurology. 1998; 50:1461-3.
12. Yoshimura DM, Aminoff MJ, Olney RK. Botulinum toxin therapy for limb dystonias. Neurology. 1992; 42:627-30.
13. Blitzer A, Brin MF, Stewart CF. Botulinum toxin management of spasmodic dysphonia (laryngeal dystonia): a 12-year experience in more than 900 patients. Laryngoscope. 1998; 108:1435-41.
14. Freund B, Schwartz M. The use of botulinum toxin for the treatment of temporomandibular disorder. Oral Health. 1998; 88:32-7.
15. Fock J, Galea MP, Stillman BC et al. Functional outcome following botulinum toxin A injection to reduce spastic equinus in adults with traumatic brain injury. Brain Inj. 2004; 18:57-63.
16. Yablon SA, Agana BT, Ivanhoe CB et al. Botulinum toxin in severe upper extremity spasticity among patients with traumatic brain injury: an open-labeled trial. Neurology. 1996; 47:939-44.
17. Brashear A, Gordon MF, Elovic E et al. Botox Post-Stroke Spasticity Study Group. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Engl J Med. 2002; 347:395-400.
18. Brashear A, McAfee AL, Kuhn ER et al. Treatment with botulinum toxin type B for upper-limb spasticity. Arch Phys Med Rehabil. 2003; 84:103-7.
19. Snow BJ, Tsui JK, Bhatt MH et al. Treatment of spasticity with botulinum toxin: a double-blind study. Ann Neurol. 1990; 28:512-5.
20. Koman LA, Mooney JF III, Smith BP et al. Management of spasticity in cerebral palsy with botulinum-A toxin: report of a preliminary, randomized, double-blind trial. J Pediatr Orthop. 1994; 14:299-303.
21. Wissel J, Heinen F, Schenkel A et al. Botulinum toxin A in the management of spastic gait disorders in children and young adults with cerebral palsy: a randomized, double-blind study of "high-dose" versus "low-dose" treatment. Neuropediatrics. 1999; 30:120-4.
22. Sutherland DH, Kaufman KR, Wyatt MP et al. Double-blind study of botulinum A toxin injections into the gastrocnemius muscle in patients with cerebral palsy. Gait Posture. 1999; 10:1-9.
23. Koman LA, Mooney JF III, Smith BP et al. BOTOX Study Group. Botulinum toxin type A neuromuscular blockade in the treatment of lower extremity spasticity in cerebral palsy: a randomized, double-blind, placebo-controlled trial. J Pediatr Orthop. 2000; 20:108-15.
24. Fehlings D, Rang M, Glazier J et al. An evaluation of botulinum-A toxin injections to improve upper extremity function in children with hemiplegic cerebral palsy. J Pediatr. 2000; 137:331-7.
25. Love SC, Valentine JP, Blair EM et al. The effect of botulinum toxin type A on the functional ability of the child with spastic hemiplegia: a randomized controlled trial. Eur J Neurol 2001; 8(suppl 5):50-8.
26. Goldman A. Treatment of axillary and palmar hyperhidrosis with botulinum toxin. Aesthetic Plast Surg. 2000; 24:280-2.
27. Naumann M, Zellner M, Toyka KV et al. Treatment of gustatory sweating with botulinum toxin. Ann Neurol. 1997; 42:973-5.
28. Naumann M, Lowe NJ. Botulinum toxin type A in treatment of bilateral primary axillary hyperhidrosis: randomized, parallel group, double blind, placebo controlled trial. BMJ. 2001; 323:596-9.
29. von Lindern JJ, Niederhagen B, Berge S et al. Frey syndrome: treatment with type A botulinum toxin. Cancer. 2000; 89:1659-63.
30. Pal PK, Calne DB, Calne S et al. Botulinum toxin A as treatment for drooling saliva in PD. Neurology. 2000; 54:244-7.
31. Dogu O, Apaydin D, Sevim S et al. Ultrasound-guided versus 'blind' intraparotid injections of botulinum toxin-A for the treatment of sialorrhoea in patients with Parkinson's disease. Clin Neurol Neurosurg. 2004; 106:93-6.
32. Bothwell JE, Clarke K, Dooley JM et al. Botulinum toxin A as a treatment for excessive drooling in children. Pediatr Neurol. 2002; 27:18-22.
33. Schurch B, Hauri D, Rodic B et al. Botulinum-A toxin as a treatment of detrusor-sphincter dyssynergia: a prospective study in 24 spinal cord injury patients. J Urol. 1996; 155:1023-9.
34. Annese V, Bassotti G, Coccia G et al. GIS-MAD Achalasia Study Group. A multicentre randomised study of intrasphincteric botulinum toxin in patients with oesophageal achalasia. Gut. 2000; 46:597-600.
35. Muehldorfer SM, Schneider TH, Hochberger J et al. Esophageal achalasia: intrasphincteric injection of botulinum toxin A versus balloon dilation. Endoscopy. 1999; 31:517-21.
36. Brisinda G, Maria G, Bentivoglio AR et al. A comparison of injections of botulinum toxin and topical nitroglycerin ointment for the treatment of chronic anal fissure. N Engl J Med. 1999; 341:65-9.
37. Mentes BB, Irkorucu O, Akin M et al. Comparison of botulinum toxin injection and lateral internal sphincterotomy for the treatment of chronic anal fissure. Dis Colon Rectum. 2003; 46:232-7.
38. Binder WJ, Brin MF, Blitzer A et al. Botulinum toxin type A (BOTOX) for treatment of migraine headaches: an open-label study. Otolaryngol Head Neck Surg. 2000; 123:669-76.
39. Silberstein S, Mathew N, Saper J et al. BOTOX Migraine Clinical Research Group. Botulinum toxin type A as a migraine preventive treatment. Headache. 2000; 40:445-50.
40. Ondo WG, Vuong KD, Derman HS. Botulinum toxin A for chronic daily headache: a randomized, placebo-controlled, parallel design study. Cephalalgia. 2004; 24:60-5.
41. Smuts JA, Baker MK, Smuts M et al. Prophylactic treatment of chronic tension-type headache using botulinum toxin type A. Eur J Neurol. 1999; 6(suppl 4):S99-S102.
42. Foster L, Clapp L, Erickson M et al. Botulinum toxin A and chronic low back pain: a randomized, double-blind study. Neurology. 2001; 56:1290-3.
43. Lang AM. A pilot study of botulinum toxin type A (Botox®), administered using a novel injection technique, for the treatment of myofascial pain. Am J Pain Manage. 2000; 10:108-12.
44. Porta M. A comparative trial of botulinum toxin type A and methylprednisolone for the treatment of myofascial pain syndrome and pain from chronic muscle spasm. Pain. 2000; 85:101-5.
45. Royal MA, Gunyea I, Bhakta B et al. Botulinum toxin type A in the treatment of refractory myofascial pain. Neurology. 2001; 56(suppl 3):A350. Abstract.
46. Freund BJ, Schwartz M. Treatment of chronic cervical-associated headache with botulinum toxin A: a pilot study. Headache. 2000; 40:231-6.
47. Naumann M, Jankovic J. Safety of botulinum toxin type A: a systematic review and meta-analysis. Curr Med Res Opin. 2004; 20:981-90.
48. National Library of Medicine. Medline Plus: strabismus. Available at: www. nlm.nih.gov/medlineplus/ency/article/001004.htm. (Accessed 23 July 2004.)
49. American Association for Ophthalmology and Strabismus. Adult strabismus general information. Available at: www. aapos.org/Strabismusgeneral.htm. (Accessed 23 July 2004.)
50. Benign Essential Blepharospasm Research Foundation. BEBRF blepharospasm pages. Available at: www.blepharospasm. org/#A8. (Accessed 22 July 2004.)
51. Dystonia Medical Research Foundation. Dystonia defined. Available at: www. dystonia-foundation.org/. (Accessed 22 July 2004.)
52. Kessler KR, Skutta M, Benecke R. Long-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency. German Dystonia Study Group. J Neurol. 1999; 246:265-74.
53. Lew MF, Adornato BT, Duane DD et al. Botulinum toxin type B: a double-blind, placebo-controlled, safety and efficacy study in cervical dystonia. Neurology. 1997; 49:701-7.
54. Lew MF, Brashear A, Factor S. The safety and efficacy of botulinum toxin type B in the treatment of patients with cervical dystonia: summary of three controlled clinical trials. Neurology. 2000; 55(suppl 5):S29-35.
55. Brin MF, Lew MF, Adler CH et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology. 1999; 53:1431-8.
56. Brashear A, Lew MF, Dykstra DD et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia. Neurology. 1999; 53:1439-46.
57. Dionne RA. Pharmacologic treatments for temporomandibular disorders. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1997; 83:134-42.
58. American Heart Association. Heart disease and stroke statistics-2004 update. Dallas, TX: American Heart Association; 2003. Available at: www.americanheart. org/downloadable/heart. (Accessed 27 July 2004.)
59. National Multiple Sclerosis Society. Who gets MS? Available at: www. nationalmssociety.org/Who% 20gets%20MS.asp. (Accessed 27 July 2004.)
60. National Multiple Sclerosis Society. Controlling spasticity in MS. Available at: www.nationalmssociety.org/Brochures-Controlling%20Sp.asp. (Accessed 27 July 2004.)
61. Sharma RR, Mathad NV, Joshi DN et al. Persistent facial myokymia: a rare pathognomic physical sign of intrinsic brain-stem lesions: report of 2 cases and review of literature. J Postgrad Med. 1992; 38:37-40, 40A-B.
62. March of Dimes Birth Defects Foundation. Cerebral palsy. Available at: www.marchofdimes.com/professionals/681_1208.asp. (Accessed 27 July 2004.)
63. National Institute of Neurological Disorders and Stroke. NINDS cerebral palsy information page. Available at: www. ninds.nih.gov/health_and_medical/ disorders/cerebral_palsy.htm. (Accessed 27 July 2004.)
64. National Institute of Neurological Disorders and Stroke. NINDS spasticity information page. Available at: www.ninds. nih.gov/health_and_medical/ disorders/spasticity_doc.htm. (Accessed 27 July 2004.)
65. Satkunam LE. Rehabilitation medicine: 3. Management of adult spasticity. CMAJ. 2003; 169:1173-9.
66. Gracies JM, Elovic E, McGuire J et al. Traditional pharmacological treatments for spasticity. Part I: Local treatments. Muscle Nerve Suppl 1997; 6:561-91.
67. Gracies JM, Nance P, Elovic E et al. Traditional pharmacological treatments for spasticity. Part II: General and regional treatments. Muscle Nerve Suppl. 1997; 6:592-120.
68. Brin MF. Dosing, administration, and a treatment algorithm for use of botulinum toxin A for adult-onset spasticity. Spasticity Study Group. Muscle Nerve Suppl. 1997; 6:S208-20.
69. Goldstein EM. Spasticity management: an overview. J Child Neurol. 2001; 16:16-23.
70. International Hyperhidrosis Society. Understanding hyperhidrosis. Available at: www.sweathelp.org/understanding/understanding.asp. (Accessed 23 July 2004.)
71. National Organization for Rare Disorders, Inc. Frey's syndrome. Available at: www.rarediseases.org/search/rdbdetail_abstract.html?disname=Frey%27s% 20Syndrome. (Accessed 23 July 2004.)
72. Hockstein NG, Samadi DS, Gendron K et al. Sialorrhea: a management challenge. Am Fam Physician. 2004; 69:2628-34.
73. Odergren T, Tollback A, Borg J. Efficacy of botulinum toxin for cervical dystonia. A comparison of methods for evaluation. Scand J Rehabil Med. 1994; 26:191-5.
74. Greene P, Kang U, Fahn S et al. Double-blind, placebo-controlled trial of botulinum toxin injections for the treatment of spasmodic torticollis. Neurology. 1990; 40:1213-8.
75. Tsui JK, Fross RD, Calne S et al. Local treatment of spasmodic torticollis with botulinum toxin. Can J Neurol Sci. 1987; 14(3 suppl):533-5.
76. Barwood S, Baillieu C, Boyd R et al. Analgesic effects of botulinum toxin A: a randomized, placebo-controlled clinical trial. Dev Med Child Neurol. 2000; 42:116-21.
77. National Headache Foundation. NHF Headache Facts. Available at: www. headaches.org/consumer/generalinfo/factsheethtml. (Accessed 22 July 2004.)
78. Hu XH, Markson LE, Lipton RB et al. Burden of migraine in the United States: disability and economic costs. Arch Intern Med. 1999; 159:813-8.
79. Beth Israel Medical Center Department of Pain Medicine and Palliative Care. Pain Medicine. Available at: www.stoppain. org/pain_medicine/headache. html. (Accessed 22 July 2004.)
80. Blumenfeld AM, Binder W, Silberstein SD et al. Procedures for administering botulinum toxin type A for migraine and tension-type headache. Headache. 2003; 43:884-91.
81. Yazici Y, Gibofsky A. A diagnostic approach to musculoskeletal pain. Clin Cornerstone. 1999; 2:1-10.
82. Reynard JM, Vass J, Sullivan ME et al. Sphincterotomy and the treatment of detrusor-sphincter dyssynergia: current status, future prospects. Spinal Cord. 2003; 41:1-11.
83. National Library of Medicine. Medline Plus: achalasia. Available at: www.nlm. nih.gov/medlineplus/ency/article/O00267.htm. (Accessed 23 July 2004.)
84. Utzig MJ, Kroesen AJ, Buhr HJ. Concepts in pathogenesis and treatment of chronic anal fissure-a review of the literature. Am J Gastroenterol. 2003; 98:968-74.
85. Lindsey I, Jones OM, Cunningham C et al. Chronic anal fissure. Br J Surg. 2004; 91:270-9.